Triple threat: new combo aims to boost kidney cancer treatment
NCT ID NCT06708949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a third drug (relatlimab) to a standard two-drug combination (nivolumab and ipilimumab) works better for advanced kidney cancer that hasn't been treated before. About 15 adults with stage IV clear cell kidney cancer will receive either the three-drug or two-drug regimen. The main goal is to check safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA, CLEAR CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
-
Penn Medicine Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States